AIM: Endothelial membrane hyperpolarization mediated by KCa3.1 and KCa2.3 channels has been demonstrated to initiate endothelium-derived hyperpolarizing factor (EDHF)-type vasodilations. Moreover, pharmacological potentiation of KCa3.1/KCa2.3 channels has been suggested to improve EDHF-type vasodilations. Herein, we determined whether the KCa3.1/KCa2.3 activator SKA-31 and its derivative SKA-20 improve endothelial dysfunction in KCa3.1-/- and NOS3-/- mice. METHODS: Membrane potentials were measured using patch-clamp electrophysiology on carotid artery (CA) endothelial cells (CAEC) from wild-type (wt) and KCa3.1-/- mice. Endothelium-dependent vasodilations were determined by pressure myography in CA. RESULTS: SKA-31 (1 μm) activated KCa3.1 and KCa2.3 channels and induced membrane hyperpolarization in CAEC of wt (ΔMP -45 mV). These responses were significantly reduced in CAEC of KCa3.1-/- (ΔMP -8 mV). SKA-31 (200 nm, 500 nm) and SKA-20 (300 nm) significantly enhanced EDHF vasodilations in wt. SKA-20 also improved vasodilations during NO synthesis. In KCa3.1-/-, the defective EDHF vasodilations were unchanged at 200 nm SKA-31, but were significantly improved at 500 nm. EDHF vasodilations were slightly enhanced at 300 nm SKA-20, but vasodilations during NO synthesis were unchanged. SKA-31 (500 nm) enhanced the impaired endothelium-dependent vasodilation in NOS3-/- mice twofold. Pharmacological inhibition of the soluble epoxide hydrolase by t-AUCB (1 μm) in contrast did not increase ACh-induced EDHF- or NO-mediated vasodilations in wt and KCa3.1-/-. CONCLUSION: Normal and defective endothelium-dependent vasodilations in murine carotid arteries can be improved by pharmacological enhancement of KCa3.1/KCa2.3 functions. These findings further support the concept that pharmacological activation of endothelial KCa2.3/KCa3.1 could offer a novel endothelium-specific antihypertensive strategy.
AIM: Endothelial membrane hyperpolarization mediated by KCa3.1 and KCa2.3 channels has been demonstrated to initiate endothelium-derived hyperpolarizing factor (EDHF)-type vasodilations. Moreover, pharmacological potentiation of KCa3.1/KCa2.3 channels has been suggested to improve EDHF-type vasodilations. Herein, we determined whether the KCa3.1/KCa2.3 activator SKA-31 and its derivative SKA-20 improve endothelial dysfunction in KCa3.1-/- and NOS3-/- mice. METHODS: Membrane potentials were measured using patch-clamp electrophysiology on carotid artery (CA) endothelial cells (CAEC) from wild-type (wt) and KCa3.1-/- mice. Endothelium-dependent vasodilations were determined by pressure myography in CA. RESULTS:SKA-31 (1 μm) activated KCa3.1 and KCa2.3 channels and induced membrane hyperpolarization in CAEC of wt (ΔMP -45 mV). These responses were significantly reduced in CAEC of KCa3.1-/- (ΔMP -8 mV). SKA-31 (200 nm, 500 nm) and SKA-20 (300 nm) significantly enhanced EDHF vasodilations in wt. SKA-20 also improved vasodilations during NO synthesis. In KCa3.1-/-, the defective EDHF vasodilations were unchanged at 200 nm SKA-31, but were significantly improved at 500 nm. EDHF vasodilations were slightly enhanced at 300 nm SKA-20, but vasodilations during NO synthesis were unchanged. SKA-31 (500 nm) enhanced the impaired endothelium-dependent vasodilation in NOS3-/- mice twofold. Pharmacological inhibition of the soluble epoxide hydrolase by t-AUCB (1 μm) in contrast did not increase ACh-induced EDHF- or NO-mediated vasodilations in wt and KCa3.1-/-. CONCLUSION: Normal and defective endothelium-dependent vasodilations in murine carotid arteries can be improved by pharmacological enhancement of KCa3.1/KCa2.3 functions. These findings further support the concept that pharmacological activation of endothelial KCa2.3/KCa3.1 could offer a novel endothelium-specific antihypertensive strategy.
Authors: Brandon T Larsen; Hiroto Miura; Ossama A Hatoum; William B Campbell; Bruce D Hammock; Darryl C Zeldin; John R Falck; David D Gutterman Journal: Am J Physiol Heart Circ Physiol Date: 2005-10-28 Impact factor: 4.733
Authors: Hong Ding; Michael Hashem; William B Wiehler; Winnie Lau; Jacqueline Martin; Julianne Reid; Chris Triggle Journal: Br J Pharmacol Date: 2005-12 Impact factor: 8.739
Authors: Stephen L Archer; Ferrante S Gragasin; Xichen Wu; Shaohua Wang; Sean McMurtry; Daniel H Kim; Michael Platonov; Arvind Koshal; Kyoko Hashimoto; William B Campbell; J R Falck; Evangelos D Michelakis Journal: Circulation Date: 2003-02-11 Impact factor: 29.690
Authors: Dorte Strøbaek; Lene Teuber; Tino D Jørgensen; Philip K Ahring; Katrine Kjaer; Rie S Hansen; Søren Peter Olesen; Palle Christophersen; Bo Skaaning-Jensen Journal: Biochim Biophys Acta Date: 2004-10-11
Authors: Marie Billaud; Alexander W Lohman; Scott R Johnstone; Lauren A Biwer; Stephanie Mutchler; Brant E Isakson Journal: Pharmacol Rev Date: 2014-03-26 Impact factor: 25.468
Authors: Aida Oliván-Viguera; Marta Sofía Valero; Estéfano Pinilla; Sara Amor; Ángel Luis García-Villalón; Nichole Coleman; Celia Laría; Víctor Calvín-Tienza; Ángel-Luis García-Otín; José M Fernández-Fernández; M Divina Murillo; José A Gálvez; María D Díaz-de-Villegas; Ramón Badorrey; Ulf Simonsen; Luis Rivera; Heike Wulff; Ralf Köhler Journal: Basic Clin Pharmacol Toxicol Date: 2016-02-29 Impact factor: 4.080
Authors: Ramesh C Mishra; Barry D Kyle; Dylan J Kendrick; Daniyil Svystonyuk; Teresa M Kieser; Paul W M Fedak; Heike Wulff; Andrew P Braun Journal: Metabolism Date: 2020-10-08 Impact factor: 8.694